Clinical Trial Details

EORTC-16032-18031

Back to Clinical Trials Database

Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma

Study documentation

Trial Status All trial activities ended
Dates Date of activation: 12-May-2004
Date Step1 close: 24-Jan-2007
Date Step2 close: 24-Jan-2007
Data management at EORTC Yes
Design Phase 2
Randomized open label
Targeted Sample size EORTC Groups: 68
Treatment MAGE3-AS02B, MAGE3-AS15
Study Staff
Type of cancer
Participating groups EORTC Melanoma Group
Protocol summary http://clinicaltrials.gov/ct/show/NCT00086866
NCT number NCT00086866
EudraCT 2004-001937-40